drugset / Trial / NCT04894188

Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer

NCT04894188

Recruiting 38 enrolled National Taiwan University Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy can fight prostate cancer by androgen deprivation. It is not yet known if neoadjuvant radiation therapy is a more effective therapy for high-risk prostate cancer. PURPOSE: Two-stage randomized trial to compare the effectiveness and safety of neoadjuvant radiotherapy and hormone therapy followed by radical prostatectomy in men with high-risk locally advanced prostate cancer

Timeline

Start
2022-01-27
Primary completion
2024-07-01
Completion
2041-07-01

Drugs

EvaluationDrugModalityDoseRoute
Background Goserelin Other / unclassified 3.6 mg Subcutaneous

Indications